Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Latest Information Update: 10 Nov 2024
Price :
$35 *
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms guardian-4
- Sponsors Novo Nordisk
- 28 Dec 2018 Status changed from active, no longer recruiting to completed.
- 21 Dec 2018 This trial was completed in Austria (end date: 2018-12-05), according to European Clinical Trials Database record.
- 16 Nov 2018 This trial was completed in Spain, according to European Clinical Trials Database.